ACTI (ACTI) News
Follow ACTI (ACTI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Active Biotech Says Japan Grants Patent For Laquinimod Ophthalmic Formulation
Active Biotech AB publ OMXSTO:ACTI
NEWS | Sep 30, 2026, 09:06 AM UTC
L
Active Biotech AB (publ) (ACTI) Secures Japan Patent for Laquinimod Eye Drop to 2042
Active Biotech AB (publ) received a Japan patent (No. 7918190) covering its laquinimod ophthalmic formulation, providing potential market exclusivity in Japan until 2042. The drug targets severe inflammatory eye diseases
NEWS | Sep 30, 2026, 09:00 AM UTC